Most pancreatic neuroendocrine tumors (PNETs) do not produce excess hormones and are therefore considered 'non-functional' [1] [2] [3] . As clinical behaviors vary widely and distant metastases are eventually lethal 2,4 , biological classifications might guide treatment. Using enhancer maps to infer gene regulatory programs, we find that non-functional PNETs fall into two major subtypes, with epigenomes and transcriptomes that partially resemble islet α-and β-cells. Transcription factors ARX and PDX1 specify these normal cells, respectively 5, 6 , and 84% of 142 non-functional PNETs expressed one or the other factor, occasionally both. Among 103 cases, distant relapses occurred almost exclusively in patients with ARX + PDX1 − tumors and, within this subtype, in cases with alternative lengthening of telomeres. These markedly different outcomes belied similar clinical presentations and histology and, in one cohort, occurred irrespective of MEN1 mutation. This robust molecular stratification provides insight into cell lineage correlates of non-functional PNETs, accurately predicts disease course and can inform postoperative clinical decisions.
, and 84% of 142 non-functional PNETs expressed one or the other factor, occasionally both. Among 103 cases, distant relapses occurred almost exclusively in patients with ARX + PDX1 − tumors and, within this subtype, in cases with alternative lengthening of telomeres. These markedly different outcomes belied similar clinical presentations and histology and, in one cohort, occurred irrespective of MEN1 mutation. This robust molecular stratification provides insight into cell lineage correlates of non-functional PNETs, accurately predicts disease course and can inform postoperative clinical decisions.
Surgery is recommended for solitary PNETs larger than 2 cm and the World Health Organization (WHO) grade is the best current tool to predict metastasis 7, 8 . Insulinomas resemble normal pancreatic β-cells and carry a good prognosis 1, 2 , but the lineage of most non-functional PNETs is obscure and about half the cases progress to lethal metastasis months to years after surgery 1, 2, 9 . Although 70% of PNETs carry MEN1, ATRX or DAXX gene mutations, and 15% activate mammalian target of rapamycin signaling 10, 11 , no mutation or biological feature is sufficiently correlated with clinical outcomes to guide prognosis or therapy 3, 8 . Alternative lengthening of telomeres (ALT) is associated with ATRX or DAXX loss and elevated risk of recurrence [12] [13] [14] , but is not a routine clinical test. Cellular identities are encoded in chromatin states defined by the complement of active cis-elements, where nucleosomes bear H3K4me1/2, H3K27ac and other covalent marks 15, 16 . 'Super' or 'stretch' enhancers, which control lineage-specifying genes 17, 18 , especially delineate cell-specific chromatin signatures 19 and help nominate tumor cell origins 20 . Chromatin immunoprecipitation sequencing (ChIP-seq)-derived profiles of H3K27ac-marked candidate enhancers in 8 frozen, primary non-functional, pancreatic and 22 intestinal neuroendocrine (NE; carcinoid) tumors (see Supplementary Table 1 ) differed substantially from those of gastrointestinal carcinomas and less so from each other (Fig. 1a) . Loci expressed in the two NE tumor types, such as SYP, were similarly marked in both, whereas organ-restricted loci, such as CDX2, were marked selectively (Fig. 1b) . Super-enhancer profiles, distinct from those of normal islets (Fig. 1c) , revealed three PNET subtypes. Considering A and B types as separate groups, 288 enhancers showed more than twofold higher H3K27ac in type A (false discovery rate (FDR) < 0.05-see Supplementary Table 2) , with sites in α-cell-specific loci ARX and IRX2 showing especially large differences (Fig. 1d) . Conversely, 104 regions showed notably more H3K27ac in B-type tumors, including enhancers over genes such as PDX1 and SLC17A6, which are not expressed in α-cells 21, 22 . Across the eight PNETs, A-and B-type tumors gave strong H3K27ac signals at ARX and IRX2 or at PDX1, respectively, whereas
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Letters NATURE MEDiciNE C-type tumors were variably marked at these loci and expressed low levels of ARX and PDX1 messenger RNAs (mRNAs) (see Extended Data Fig. 1a ). In individual A-and B-type tumors, ARX and PDX1 met objective super-enhancer criteria 19 , respectively (Fig. 1e) . At these and other loci, ChIP-seq for H3K4me2 (ref.
23
) on the original eight and four additional PNETs (see Supplementary Table 1) revealed similar patterns to H3K27ac (see Extended Data Fig. 1a H3K4me2 marks the PDX1 promoter in all PNETs, but only B-type tumors carry locus-wide H3K4me2). Aggregate (Fig. 1f) and individual (see Extended Data Fig. 1b) comparisons of A-and B-type PNET transcriptomes (see Supplementary Table 3) showed differential ARX and PDX1 expression.
Knowledge of pancreatic endocrine ontogeny derives largely from studies of mouse development 24 . NEUROG3 initiates the endocrine lineage and ARX specifies α-cell fate 5 , whereas PAX4 drives β-cell differentiation 25 ; absence of both factors favors the δ lineage 26 . ARX is necessary for α-cell differentiation 27 , but other transcription factors (TFs, for example NKX2.2, PAX6, PDX1) sustain β-cells 6, [28] [29] [30] [31] . In embryos, early α-cell specification leads to Insulin and Glucagon co-expressing bipotential precursors, followed by β-cell differentiation 32 ; forced transdifferentiation between α-and β-cells also occurs through intermediate Insulin
+

Glucagon
+ cells 29 . In this light, we compared A-and B-type PNETrestricted enhancers (Fig. 1d) with areas of chromatin selectively open in normal α-or β-cells 33 . Type A regions were highly enriched for α-cell-specific sites (62 shared, P < 1.1 × 10 −18 ), whereas type B-specific enhancers were enriched for β-cell-restricted sites (15 shared, P < 1.7 × 10 −5 ; see Supplementary Table 4) . Comparison with RNA profiles of fractionated normal human islets 34 also revealed enrichment of α-and β-cell-specific transcripts in A-(P < 1.6 × 10 −9 ) and B-type (P < 6.2 × 10 −16 ) PNETs, respectively. Differential TF expression distinguished PNETs better than Glucagon and Insulin mRNA levels, which were generally low and similar in the two subtypes (see Extended Data Fig. 1b) .
From H3K27ac ChIP-seq on 13 additional frozen PNETs (validation cohort), tumors were designated as: type A if signals were high (>500 reads per kb per million sequence tags (RPKM)) at ARX and IRX2 but absent or low (<250 RPKM) at PDX1; type B if the ARX locus was largely unmarked (<250 RPKM); and type C if read counts at ARX and PDX1 were comparable. Although A or C typing was ambiguous in two PNETs, the B type was easily identified by lack of H3K27ac at ARX. Similar to the discovery set, the validation cohort readily distinguished type B from other PNETs by H3K27ac signals at α-cell/type A-and β-cell/type B-specific enhancers ( Fig. 2 and see Extended Data Fig. 1c) . Moreover, ARX and PDX1 immunostains gave the expected signals in normal human islets (see Extended Data Fig. 2a,b) and, importantly, 15 independent, additional, non-functional PNETs showed mutually exclusive, nucleusdominant, ARX or PDX1 expression in 10 tumors (67%); 5 cases lacked or co-expressed both TFs (Fig. 3a) . 
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Next tissue microarrays were examined that represented 77 Dutch PNETs 35 , 61 of which (79%) had germline MEN1 mutations, including 13 insulinomas associated with hyperinsulinemia (see Supplementary Table 5 ). Overall, 34 of the 77 cases showed nuclear expression of ARX only (31% type A), 31 expressed only PDX1 (37% type B) and 12 cases were either double-positive (DP) or double-negative (DN-8% each; Fig. 3b and see Extended Data (Fig. 3b ).
H3K4me2 and mRNAs were profiled in selected tumors from the Dutch cohort using fixed-tissue chromatin immunoprecipitation sequencing (FiT-seq) 36 and RNA sequencing (RNA-seq). PNETs, identified by IHC as ARX + or PDX1 + , expressed exclusively those mRNAs and showed abundant H3K4me2 only at the corresponding super-enhancers; DP tumors (type C) expressed both ARX and PDX1 mRNAs, with less pronounced enhancer marks at both loci (Fig. 3d) . Of note, no PNETs in this group expressed somatostatin (SST) (see Extended Data Fig. 3b ). FiT-seq for H3K27ac and immunostaining on representative formalin-fixed, paraffin-embedded (FFPE) samples from the discovery cohort also revealed concordance (see Extended Data Fig. 3c ). Thus, IHC classifies PNETs robustly, reflecting lineage-specific gene and enhancer signatures that are henceforth called ARX
+ and DP. PNETs uniformly lacked H3K27ac and mRNA expression at early acting NEUROG3 and PAX4 loci (see Extended Data Fig. 4a ), similar to isolated human islets, and IHC failed to detect NEUROG3 in any tumor (see Extended Data Fig. 4b ). In contrast, enhancer marking and mRNA levels were high at other canonical endocrine loci (ISL1 and NEUROD1-data not shown), but not at terminal differentiation genes (for example, MAFA and FFAR1; see Extended Data Fig. 4c ). H3K4me2, but not H3K27ac, appeared at many such loci and, because PNETs may represent arrested differentiation, we compared tumor mRNA profiles with those of normal mature and progenitor islet cells 37 (see Supplementary Table 6 ). In all PNETs with mRNA data, the mature cell signature was stronger than that of progenitors (see Extended Data + non-functional PNETs partially resemble mature α-and beta β-cells, respectively.
Detailed clinical follow-up was documented on the 61 Dutch MEN1-mutant cases 38 (see Supplementary Table 5) . ARX + and PDX1
+ non-functional PNETs (n = 47) did not differ by tumor size or grade (Fig. 4a) , and the range of sizes was similar to that of insulinomas (see Extended Data + and two DP tumors relapsed. Thus, PDX1 expression correlated with favorable prognosis in two distinct PNET cohorts.
Telomere-specific FISH was used to determine ALT status, which is associated with ATRX and DAXX mutations 
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or >3 cm (9.6, CI 1.94-47.44). Relapses occurred in patients with WHO grade 1 PNETs, and considering all variables by multiple logistic regression, tumor grade was a poor independent risk factor (Fig. 4f) . Only ALT and especially absence of PDX1 correlated independently with relapse (Fig. 4f) ; PDX1 + PNETs rarely relapsed. In summary, enhancer profiles in overtly similar non-functional PNETs revealed superficial similarities with islet α-or β-cells, reflected in IHC delineation of ARX + , PDX1 + and fewer ARX + PDX + (DP) tumors. Among 103 cases followed at length after surgery, distant relapses predominated in patients with ARX + tumors, occurring in only three PDX1 + or DP cases. This favorable association with PDX1 expression can be applied rapidly in the clinic. Specifically, patients with small PDX1 + tumors may be reassured and followed conservatively, whereas vigilant monitoring in patients with PDX1
− tumors may detect early metastases amenable to surgical or medical treatment. Consideration of ALT + status, which correlates with ARX expression, adds prognostic information, but is less practical than IHC in clinical laboratories. The superior prognosis of PDX1
+ over ARX + PNETs matches the indolent and aggressive disease courses, respectively, of sections were macrodissected to obtain >80% tumor cell enrichment and 10 sections were used, each 10-μm thick. Sections were washed three times with xylenes to remove paraffin, rehydrated in an ethanol/water series and prepared as described 36 , with modified buffer and sonication conditions (Covaris E220 instrument, 20 min, 5% duty cycle, 105 peak incident power, 200 cycles per burst, 1 ml AFA Fiber milliTUBEs). Soluble chromatin (5 µg) was immunoprecipitated with 10 μg H3K27ac (Active Motif 39133) antibody for ChIP-seq and H3K4me2 (Millipore 07-030) or H3K27ac (Diagenode C15410196) antibody for FiTseq. ChIP-seq libraries were constructed by end repair (Epicentre ER0720) of precipitated DNA, base extension with Klenow fragment (New England Biolabs M0212L) and ligation (New England Biolabs M220S) of Y-form-sequencing adapters (Illumina), followed by 14 cycles of PCR. Between enzymatic steps, fragments of the desired size were enriched using AMPure XP beads (Beckman Coulter). FiT-seq libraries were prepared using ThruPLEX-FD kits (Rubicon Genomics) following the manufacturer's protocols. Then, 36-base-pair (bp) pairedend reads were sequenced on a HiSeq 2500 instrument (Illumina).
RNA-seq.
A small piece of each snap-frozen primary tumor was pulverized using the T-prep method (Covaris, catalog no. 520097) on dry ice, followed by implementation of Agencourt RNAadvance (Beckman Coulter, catalog no. A32645) on a Biomek FXP automation workstation (Beckman Coulter) to isolate RNA. We used 150 ng RNA to prepare libraries with TruSeq Stranded Total RNA kits (Illumina, catalog no. RS-122-2301). From FFPE tissues, four 10-μm sections were deparaffinized, rehydrated in an ethanol/water series, and RNA extracted using AllPrep DNA/RNA FFPE kits (Qiagen). Concentrations were measured using the Quant-iT RiboGreen RNA assay (Thermo Fisher) and the quality assessed on an Agilent 2100 Bioanalyzer using the Agilent RNA 6000 Nano kit. Ribosomal (rRNA) and mitochondrial RNAs were removed using biotinylated, target-specific oligonucleotides combined with Ribo-Zero rRNA removal beads and the TruSeq Stranded Total RNA kit (Illumina). The 75-bp single-end reads were sequenced on a NextSeq 500 Instrument (Illumina).
Immunostaining. Tissue sections were deparaffinized in xylenes and hydrated through an ethanol and water series. Antigens were retrieved in 10 mM sodium citrate (pH 6) and 0.05% Tween-20 in a pressure cooker for 3 min. After cooling and rinsing with PBS, slides were treated with 3% H 2 O 2 in PBS for 10 min to quench endogenous peroxidases, washed and incubated in blocking solution (PBS containing 1% BSA and 1% Tween-20) for 1 h at ambient temperature. Slides were incubated with ARX (Thermo Fisher AF7068SP, dilution 1:300), PDX1 (Abcam ab134150, 1:300), NEUROG3 (Fisher Scientific AB5684, 1:50) or SST (Agilent A056601-2, 1:10,000) antibody diluted in blocking solution for 1 h. Slides stained for PDX1, SST or NEUROG3 were washed in PBS and incubated with the peroxidase-based EnVision Kit (Dako). Slides stained for ARX were incubated with horse radish peroxidase-conjugated anti-sheep antibody (Santa Cruz sc-2473, 1:500 in blocking solution) for 30 min, followed by VectaStain Elite ABC kit (Vector) for 30 min, washed, developed using 3,3′-diaminobenzidine (Dako) and counterstained with Mayer's hematoxylin. For double immunostaining, slides were blocked with 5% FBS in PBS for 1 h at room temperature and incubated overnight at 4 °C with ARX (1:100 in PBS, 1% BSA, 0.3% Triton X-100) and PDX1 (1:500) antibody. Slides were then incubated with a biotinylated antisheep antibody (Life Technologies A16045, 1:250), followed by a mix of Alexa Fluor 488-conjugated streptavidin (Life Technologies S11223) and Alexa Fluor 546-conjugated anti-rabbit serum antibody (Life Technologies A11035, 1:250) for 1 h, washed in PBS and mounted in DAPI + Vectashield medium (Vector). Associations of TF expression with clinical variables were calculated using the statistical package SPSS v.19.0.0.
Telomere-specific FISH and assessment of ALT. Deparaffinized TMA slides were hydrated, steamed for 25 min in citrate buffer (Vector Laboratories), dehydrated, and hybridized with a Cy3-labeled peptide nucleic acid probe complementary to the mammalian telomere repeat sequence. An Alexa Fluor 488-labeled peptide nucleic acid probe specific to human centromeric DNA was included as a positive control. After post-hybridization washes, slides were counterstained with DAPI. ALT + tumors were identified by telomere length heterogeneity and the presence of large, ultra-bright foci of nuclear FISH signals in ≥1% of tumor cells 12, 14 . Necrotic areas were excluded from consideration and two individuals blinded to the PNET subtype scored the slides, with 100% concordance.
Computational and statistical analyses. ChIP-seq reads were aligned to the reference genome (hg19) using BWA 0.7.10 (ref. 41 ). Reads with mapping scores <10 were discarded, and those aligned to the same position and strand were counted only once. Density signals were calculated using igvtools and visualized on the Integrated Genome Viewer 42 . H3K27ac and H3K4me2 peaks (style 'histone' for variable length, local filtering disabled) were called using HOMER 43 . A union set of H3K27ac + peaks was generated by taking the top 50,000 from each sample and merging those peaks using bedtools merge 44 . Reads were acetylation signals at enhancers, estimated from ChIP-seq reads that fell within this union set and counted using featureCounts 45 . H3K27ac profiles were compared using DESeq2 (ref. 46 ). Promoter signals (<2 kb downstream and <2.5 kb upstream of transcription start sites) vary less than those at enhancers; therefore, only promoter signals were used to estimate normalization (size) factors for each library by DESeq2. When comparing libraries normalized by these size factors, only enhancers with average normalized read counts ≥100 were considered. P values were calculated using Wald's test and FDRs using the Benjamini-Hochberg method 47 . Super-enhancers were called by ROSE 19 from H3K27ac peaks using default parameters. Public H3K27ac ChIP-seq data, obtained from the following sources, were re-analyzed using the above methods:
Pancreatic ductal adenocarcinoma 48 : Gene Expression Omnibus (GEO) accessions GSM2131266 and GSM2131280 Gastric adenocarcinoma 49 : GEO accessions GSM1969645 and GSM1969657 Colorectal cancer 50 : GEO accessions GSM2058055 and GSM2058056 Normal islets 51 : ArrayExpress accession E-MTAB-1919 α-Cell-and β-cell-specific enhancers were obtained from Supplementary Table 4 in Arda et al.
33
. Enhancers shared with PNET types A (ARX + ) and B (PDX1 + ) were determined by bedtools intersect 44 , and enrichment P values were calculated using Fisher's exact test. To cluster PNETs by enhancer signatures (see Fig. 2a and Extended Data Fig. 1c ), hierarchical clustering of Pearson's correlations of H3K27ac profiles (quantified by log 2 read counts) was performed, using the shortest distance linkage.
RNA-seq reads were mapped to the hg19 reference genome using STAR 2.5.2 (ref.
52
) and GENCODE v.19 annotations; reads with mapping scores <10 were discarded. To compare RNA profiles, reads were counted with featureCounts 45 and compared using DESeq2. P values were calculated using Wald's test and FDRs using the Benjamini-Hochberg method, considering only genes with an average normalized read count ≥100 and using a Cook's cutoff of 20. RNA-seq data on normal pancreatic islets 53 were obtained from GEO accessions GSM1303932 and GSM1303934. α-Cell-and β-cell-specific genes were obtained from Supplementary Table 2 in Wang et al. 34 . Enrichment P values of α-and β-beta cell-specific genes were calculated by Fisher's exact test (two-sided). Pancreatic endocrine cell mRNA signatures were obtained from Supplementary Table 1 ALT status and PNET immunohistochemistry were compared using two-sided Fisher's exact test. Tumor sizes between groups were compared using the two-tailed Mann-Whitney U-test. Disease-free survival was analyzed using the log-rank test and Kaplan-Meier plots were generated using GraphPad Prism v.7. To assess the prognostic value of different variables, we applied SPSS Statistics for multiple logistic regression analysis.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
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All relevant data are included in the manuscript and/or in its supplementary information files. ChIP-seq and RNA-seq data have been deposited in the National Center Biotechnology Information's GEO under GSE116356. Other original data that support the findings of this study have been uploaded as Source Data. + (type B, n = 31 biologically independent samples) tumors (T) adjacent to normal islets (N), showing selective detection of ARX (green) and PDX1 (red), respectively. Lack of antibody cross-reactivity controls for ARX and PDX1 co-staining (Fig. 3c) in DP tumors. b, SST expression in normal islets (δ-cells) and absence in all 77 Dutch PNETs, including the representative DN tumor (n = 6 biologically independent samples) shown here. c, IHC results for ARX and PDX1 shown alongside H3K27ac FiT-seq data from the same samples in three of the four cases (one of each subtype) from the discovery cohort where both FFPE and frozen samples were available. 
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